I am a medical oncologist who specializes in caring for people with lung cancer. I am also a health services researcher who is interested in innovative cancer care systems that provide high quality, affordable, and sustainable care.
My graduate education at Harvard Medical School and Harvard Business School, where my work focused on improving care delivery in a resource-poor setting, gave me an appreciation for improving complex healthcare systems. I also performed research at Massachusetts General Hospital that focused on ways for leaders to make hospitals safer and graduated with honors for this work.
My research has evolved to study aspects of cancer care delivery including disparities in cancer care, the overuse of aggressive treatments at the end of life, and interventions to improve the quality of care delivery. I was selected as one of the American Society of Clinical Oncology’s inaugural health policy fellows; in this role I am working to identify and prioritize policy areas for intervention to improve the value of cancer care.
One of my patients’ top concerns is balancing treatment with quality of life. My goal for them and their caregivers is to feel like their concerns and personal goals have been heard, recognized, and incorporated into their personalized care plan.
- Clinical Expertise: Lung Cancer
- Awards and Honors: Dean's Award, Harvard Medical School, Harvard Business School; American Society of Clinical Oncology Health Policy Fellowship (2016); Conquer Cancer Foundation of ASCO Merit Award (2015, 2016)
- Languages Spoken: English
- Education: MD, Harvard Medical School; MBA, Harvard Business School
- Residencies: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Fellowships: The University of Chicago Medicine
- Board Certifications: Internal Medicine
Daly B, Olopade OI. Race, ethnicity, and the diagnosis of breast cancer. JAMA. 2015 Jan 13;313(2):141-2.
Daly B, Olopade OI. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015 May-Jun;65(3):221-38.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more